CMTA Appoints Biotech Industry Veteran Suzanne Bruhn, PhD as New CEO

GLENOLDEN, Pa., November 6, 2023 – The Charcot-Marie-Tooth Association announced

October 2023 Community Statement from Novartis

“The CMTA welcomes this community update from Novartis and applauds

CMTA Awards $225,483 for Study On Using ASOs to Treat CMT2E

The Charcot-Marie-Tooth Association (CMTA) Board of Directors announced Sept. 28

Understanding Charcot-Marie-Tooth Disease in Children

This CMT awareness month, the CMTA’s Chief Research Officer, Katherine

Muscular Dystrophy Association and Charcot-Marie-Tooth Association Announce Collaborative Non-Viral Gene Therapy Research Grant

New York, NY – September 12, 2023 — The Muscular

CMTA Hails Novartis Acquisition of DTx Pharma And Its CMT1A Therapeutic Program

The Charcot-Marie-Tooth Association July 17 hailed the news that global

Development of Treatments for CMT2D

Professor Robert Burgess and his team at The Jackson Laboratory

CMTA Updates List of Neurotoxic Meds Potentially More Hazardous to CMT Patients

The Charcot-Marie-Tooth Association (CMTA) announced the results of a review

A New Therapeutic Strategy for CMT2D

Scientists at the UCL Queen Square Institute of Neurology in

Development of Advanced Research Diagnostic Capabilities for the CMT Community

CMT is a genetic disease caused by distinct changes in